COLUMBUS, Ohio, June 15, 2011 /PRNewswire/ — EndoSphere
Inc., a medical technology company that holds 23 U.S. and
international issued and pending patents, announced today that the
U.S. Patent and Trademark Office has issued the company a patent
covering the use of its endoscopically implantable devices for the
treatment of metabolic diseases, including obesity and type 2
diabetes.
U.S. Patent number 7,931,693 titled “Method and Apparatus for
Reducing Obesity” describes a noninvasive device that uses the
body’s natural physiology to regulate appetite and satiety among
other potential uses.
“This strong initial patent position, in combination with
significant clinical interest, makes EndoSphere an attractive
partner in the rapidly growing fields of interventional
gastroenterology and obesity treatments,” commented James McKinley,
EndoSphere CEO.
Kenneth Binmoeller, M.D., EndoSphere’s co-founder and the
technology’s inventor, commented, “EndoSphere’s inventions respond
to the urgent need for a less invasive, safer and more physiologic
treatment for the growing problem of obesity worldwide.”
“Treating obesity is the first target for our technology, the
first of several major medical applications for which we plan to
develop and commercialize products,” added McKinley.
EndoSphere Inc. completed an oversubscribed Series A funding in
June 2011.
About EndoSphere Inc.
EndoSphere Inc. is a medical technology company founded in 2006.
The company develops and commercializes devices including the
SatiSphere™ duodenal insert, which treats one of the most
critical healthcare issues in the world today: obesity and its
co-morbidities. EndoSphere holds 23 U.S. and international
issued and pending patents. EndoSphere is a portfolio company
of Broadline Capital, a global private equity investment firm.
For more information, please visit <
‘/>”/>
